Astrazeneca Investors Will Question Sales Target After Trial Failure

Dow Jones07-09 20:23

1223 GMT - AstraZeneca investors will question whether the company's target of $80 billion in sales by 2030 is credible after the failed Wainua drug phase III trial, AJ Bell's Dan Coatsworth says. Shares fell 10% after the announcement, wiping 23 billion pounds off the company's market capitalization. "It's not unusual to see phase III trials fail, but AstraZeneca has had far more hits than misses so far this year," Coatsworth says. He adds that the trial failure is a reminder of the high risks that come within the industry. Shares have clawed back earlier losses and are now down 8.4% at 130.40 pounds. (ian.walker@wsj.com)

(END) Dow Jones Newswires

July 09, 2026 08:23 ET (12:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650392173?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650392173","market":"us","top_or_hot":-1,"title":"Astrazeneca Investors Will Question Sales Target After Trial Failure","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1223 GMT - AstraZeneca investors will question whether the company's target of $80 billion in sales by 2030 is credible after the failed Wainua drug phase III trial, AJ Bell's Dan Coatsworth says. Shares fell 10% after the announcement, wiping 23 billion pounds off the company's market capitalization. \"It's not unusual to see phase III trials fail, but AstraZeneca has had far more hits than misses so far this year,\" Coatsworth says. He adds that the trial failure is a reminder of the high risks that come within the industry. Shares have clawed back earlier losses and are now down 8.4% at 130.40 pounds. (ian.walker@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2026 08:23 ET (12:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astrazeneca Investors Will Question Sales Target After Trial Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstrazeneca Investors Will Question Sales Target After Trial Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-09 20:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1223 GMT - AstraZeneca investors will question whether the company's target of $80 billion in sales by 2030 is credible after the failed Wainua drug phase III trial, AJ Bell's Dan Coatsworth says. Shares fell 10% after the announcement, wiping 23 billion pounds off the company's market capitalization. \"It's not unusual to see phase III trials fail, but AstraZeneca has had far more hits than misses so far this year,\" Coatsworth says. He adds that the trial failure is a reminder of the high risks that come within the industry. Shares have clawed back earlier losses and are now down 8.4% at 130.40 pounds. (ian.walker@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2026 08:23 ET (12:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2650392173","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650392173","pubTimestamp":1783599780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1223 GMT - AstraZeneca investors will question whether the company's target of $80 billion in sales by 2030 is credible after the failed Wainua drug phase III trial, AJ Bell's Dan Coatsworth says. Shares fell 10% after the announcement, wiping 23 billion pounds off the company's market capitalization. \"It's not unusual to see phase III trials fail, but AstraZeneca has had far more hits than misses so far this year,\" Coatsworth says. He adds that the trial failure is a reminder of the high risks that come within the industry. Shares have clawed back earlier losses and are now down 8.4% at 130.40 pounds.  Dow Jones NewswiresJuly 09, 2026 08:23 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行"},"translate_title":"试验失败后阿斯利康投资者将质疑销售目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5},"content_text":"1223 GMT - AstraZeneca investors will question whether the company's target of $80 billion in sales by 2030 is credible after the failed Wainua drug phase III trial, AJ Bell's Dan Coatsworth says. Shares fell 10% after the announcement, wiping 23 billion pounds off the company's market capitalization. \"It's not unusual to see phase III trials fail, but AstraZeneca has had far more hits than misses so far this year,\" Coatsworth says. He adds that the trial failure is a reminder of the high risks that come within the industry. Shares have clawed back earlier losses and are now down 8.4% at 130.40 pounds. (ian.walker@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2026 08:23 ET (12:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650392173","isCrawlerRequest":true}